EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment   The European Investment Bank (EIB) and Atriva Therapeutics, a german biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement  to facilitate the company’s development and clinical testing of…..